Enlivex Therapeutics (ENLV) to Release Quarterly Earnings on Friday

Enlivex Therapeutics (NASDAQ:ENLV) will likely be posting its quarterly earnings results before the market opens on Friday, April 4th. Analysts expect the company to announce earnings of ($0.16) per share for the quarter.

Enlivex Therapeutics Stock Performance

Shares of NASDAQ:ENLV opened at $1.01 on Friday. The firm has a market cap of $21.62 million, a PE ratio of -1.03 and a beta of 1.11. Enlivex Therapeutics has a 52 week low of $0.81 and a 52 week high of $4.59. The firm’s fifty day moving average is $1.10 and its 200-day moving average is $1.24.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on the company. D. Boral Capital reissued a “buy” rating and issued a $13.00 price objective on shares of Enlivex Therapeutics in a research note on Monday, March 3rd. HC Wainwright lifted their target price on Enlivex Therapeutics from $6.00 to $7.00 and gave the stock a “buy” rating in a report on Monday.

Enlivex Therapeutics Company Profile

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial.